DiaMedica Therapeutics Inc. (DMAC) has a consensus analyst rating of Buy, based on 6 analysts covering the stock. Of those, 6 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for DMAC is $8.33, representing a +27.4% upside from the current price of $6.54. Price targets range from a low of $7.00 to a high of $10.00.
